C P Camargo1, R Z Pfann2, M S Kubrusly3, M F R Silva4, E T Guimarães4, M S Leite4, P H N Saldiva4, R Gemperli5. 1. Laboratório de Microcirurgia E Cirurgia Plástica, Faculdade de Medicina, Universidade de São Paulo, Avenida Dr. Arnaldo, 455/1363, São Paulo, SP, 01246903, Brazil. consultoriodracristina@gmail.com. 2. School of Medicine, Faculdade de Medicina, Universidade de São Paulo, Avenida Dr. Arnaldo, 455, São Paulo, SP, 01246903, Brazil. 3. Laboratório de Transplante de Cirurgia Do Fígado, Faculdade de Medicina, Universidade de São Paulo, Avenida Dr. Arnaldo, 455/2302, São Paulo, SP, 01246903, Brazil. 4. Laboratório de Poluição Atmosférica Experimental, Faculdade de Medicina, Universidade de São Paulo, Avenida Dr. Arnaldo, 455/1120, São Paulo, SP, 01246903, Brazil. 5. Laboratório de Microcirurgia E Cirurgia Plástica, Faculdade de Medicina, Universidade de São Paulo, Avenida Dr. Arnaldo, 455/1363, São Paulo, SP, 01246903, Brazil.
Abstract
BACKGROUND: Smoking causes a threefold increase in the risk of surgical complications in flaps. Hyperbaric oxygen therapy (HBOT) increases the viability of chronic wounds. However, there are few studies concerning the effects of HBOT on surgical flaps in patients who smoke. This study aimed to analyze the effect of HBOT on the viability of cutaneous flaps in tobacco-exposed rats. METHODS: Twenty Wistar rats were exposed to tobacco smoke for two months. Following this period, all animals underwent a dorsal cutaneous flap (3 × 10 cm) surgery and were divided into two groups: control (n = 10) and HBOT (n = 10). HBOT was performed in seven daily sessions (2 ATA, 90 min). After seven days, the animals were euthanized. The outcomes were total area, viable area, viable area/total area rate, analysis of dermal appendages and angiogenesis (hematoxylin-eosin), and gene expression analysis of iNOS and VEGF-a biomarkers. RESULTS: The HBOT group showed an increase in viable area compared with the control group (84% versus 47%, p = 0.009, respectively). The HBOT group also showed an increase in appendage units (1.69 ± 0.54 versus 1.87 ± 0.58, p = 0.04) and angiogenesis density (1.29 ± 0.45 versus 1.82 ± 0.64, p < 0.001) compared to the control group. There was a difference between the control and HBOT groups in iNOS levels (0.926 ± 1.4 versus 0.04 ± 0.1 p = 0.002, respectively). However, this study did not show a difference between the groups concerning the gene expression of VEGF-a. CONCLUSION: The use of hyperbaric oxygen therapy increased the viability of cutaneous flaps in tobacco-exposed rats and decreased iNOS mRNA levels; however, it did not change VEGF-a levels. Level of Evidence IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
BACKGROUND: Smoking causes a threefold increase in the risk of surgical complications in flaps. Hyperbaric oxygen therapy (HBOT) increases the viability of chronic wounds. However, there are few studies concerning the effects of HBOT on surgical flaps in patients who smoke. This study aimed to analyze the effect of HBOT on the viability of cutaneous flaps in tobacco-exposed rats. METHODS: Twenty Wistar rats were exposed to tobacco smoke for two months. Following this period, all animals underwent a dorsal cutaneous flap (3 × 10 cm) surgery and were divided into two groups: control (n = 10) and HBOT (n = 10). HBOT was performed in seven daily sessions (2 ATA, 90 min). After seven days, the animals were euthanized. The outcomes were total area, viable area, viable area/total area rate, analysis of dermal appendages and angiogenesis (hematoxylin-eosin), and gene expression analysis of iNOS and VEGF-a biomarkers. RESULTS: The HBOT group showed an increase in viable area compared with the control group (84% versus 47%, p = 0.009, respectively). The HBOT group also showed an increase in appendage units (1.69 ± 0.54 versus 1.87 ± 0.58, p = 0.04) and angiogenesis density (1.29 ± 0.45 versus 1.82 ± 0.64, p < 0.001) compared to the control group. There was a difference between the control and HBOT groups in iNOS levels (0.926 ± 1.4 versus 0.04 ± 0.1 p = 0.002, respectively). However, this study did not show a difference between the groups concerning the gene expression of VEGF-a. CONCLUSION: The use of hyperbaric oxygen therapy increased the viability of cutaneous flaps in tobacco-exposed rats and decreased iNOS mRNA levels; however, it did not change VEGF-a levels. Level of Evidence IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
Authors: P J C Biselli; F D T Q S Lopes; H T Moriya; D H R F Rivero; A C Toledo; P H N Saldiva; T Mauad; M A Martins Journal: Braz J Med Biol Res Date: 2011-04-01 Impact factor: 2.590
Authors: Ahmed Jamal; Brian A King; Linda J Neff; Jennifer Whitmill; Stephen D Babb; Corinne M Graffunder Journal: MMWR Morb Mortal Wkly Rep Date: 2016-11-11 Impact factor: 17.586
Authors: G S A Boersema; Z Wu; L F Kroese; S Vennix; Y M Bastiaansen-Jenniskens; J W van Neck; K H Lam; G J Kleinrensink; J Jeekel; J F Lange Journal: Int J Colorectal Dis Date: 2016-04-04 Impact factor: 2.571